Awardee OrganizationUNIV OF MASSACHUSETTS MED SCH WORCESTER
Description
Abstract Text
Project Summary
The overall goal of this proposal is to determine the mechanism by which Insulin Receptor Substrate 2 (IRS2)
regulates the spindle assembly checkpoint (SAC) and to use this information to study novel therapeutic
approaches for the treatment of triple negative breast cancer (TNBC). The IRS proteins are essential adaptor
proteins of the insulin (IR) and insulin-like growth factor-1 (IGF1R) receptors. Dysregulation of this pathway
through upregulation of receptors and ligands drives breast cancer initiation, growth and metastasis.
Unfortunately, interfering with the IIS pathway for the treatment of breast cancer by receptor/ligand-targeted
approaches has been unsuccessful, and efforts to improve the ability to target the IIS pathway for cancer therapy
are hindered by the fact that the mechanism(s) by which this signaling pathway contributes to cancer progression
are not well established. This proposal focuses on IRS2 because this adaptor protein is expressed preferentially
in TNBC, and the applicant has compelling data that IRS2 plays a causal role in the aggressive nature of this
breast cancer subtype. Understanding the mechanisms of action of IRS2 in TNBC is essential for exploiting IRS2
as a therapeutic target. In this regard, intriguing recent evidence from the applicant’s lab and other labs has
emerged that implicates IRS2 in mitotic regulation. Specifically, IRS2 expression increases during mitosis, and
it is required for cell cycle arrest at the spindle assembly checkpoint (SAC), a process that ensures precise
chromosomal segregation to maintain genome integrity. Importantly, no studies to date have established the
mechanistic role of IRS2 in SAC regulation. Toward this goal, the applicant has identified the cell cycle regulatory
kinase PLK1, which controls the SAC, as an IRS2-specific interacting protein. Together, these findings reveal a
potential IRS2-dependent vulnerability that could be exploited therapeutically, a possibility that is supported by
the applicant’s preliminary data that loss of IRS2 expression sensitizes TNBC to mitotic stress drugs. To
investigate the hypothesis that IRS2 regulation of the SAC sustains TNBC viability and that targeting this function
of IRS2 will inhibit tumor growth at both primary and metastatic sites, the applicant will: 1) Investigate the role of
IRS2 in spindle assembly checkpoint (SAC) regulation. The hypothesis that IRS2 expression and localization
are essential for efficient mitotic SAC activation will be examined; 2) Establish the molecular mechanisms by
which IRS2 regulates the mitotic SAC. The hypothesis that IRS2 promotes the fidelity of spindle formation
through the recruitment and activation of PLK1 will be examined; 3) Assess the therapeutic efficacy of targeting
IRS2-dependent cell cycle functions in TNBC. The hypothesis that acute targeting of IRS2 expression and/or its
cell-cycle regulatory functions will sensitize TNBC to mitotic stress will be examined.
Public Health Relevance Statement
Narrative
Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer that is associated with poor
patient outcomes. Triple negative tumor cells are characterized by unstable genomes, and they require the
increased activity of cellular pathways that prevent additional DNA damage and cell death. This proposal will
investigate one mechanism that protects the genome to enhance the survival of TN tumor cells, with the long-
term goal of developing new therapies to treat TNBC patients.
No Sub Projects information available for 1R01CA290778-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R01CA290778-01A1
Patents
No Patents information available for 1R01CA290778-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R01CA290778-01A1
Clinical Studies
No Clinical Studies information available for 1R01CA290778-01A1
News and More
Related News Releases
No news release information available for 1R01CA290778-01A1
History
No Historical information available for 1R01CA290778-01A1
Similar Projects
No Similar Projects information available for 1R01CA290778-01A1